Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S L Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Avinash Kambadakone, Laura M Spring, Douglas S Micalizzi, Maristela L Onozato, Dante Che, Utthara Nayar, Adam Brufsky, Kevin Kalinsky, Cynthia X Ma, Joyce O'Shaughnessy, Hyo S Han, Anthony J Iafrate, Lianne Y Ryan, Dejan Juric, Beverly Moy, Leif W Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A Haber, Aditya Bardia, Seth A Wander
PURPOSE: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), first-line treatment is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibition (CDK4/6i). After disease progression, which often comes with ESR1 resistance mutations (ESR1-MUT), which therapies to use next and for which patients are open questions. An active area of exploration is treatment with further CDK4/6i, particularly abemaciclib, which has distinct pharmacokinetic and pharmacodynamic properties compared with the other approved CDK4/6 inhibitors, palbociclib and ribociclib...
May 2023: JCO Precision Oncology